142 related articles for article (PubMed ID: 34302842)
1. Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.
Tandjaoui-Lambiotte Y; Akrour Y; Gibelin A; Gonzalez F; Stoclin A; Moreau AS; Jaubert P; Oppenheimer A; Duchemann B; Gaudry S
Chest; 2022 Jan; 161(1):284-287. PubMed ID: 34302842
[No Abstract] [Full Text] [Related]
2. Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma.
Giroux-Leprieur E; Dumenil C; Chinet T
J Thorac Oncol; 2018 Nov; 13(11):e232-e234. PubMed ID: 30368417
[No Abstract] [Full Text] [Related]
3. Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.
Farris M; Larkin-Kaiser KA; Scory T; Boyne D; Wilner KD; Pastel M; Cappelleri JC; Ivanova JI
Future Oncol; 2020 Dec; 16(36):3107-3116. PubMed ID: 32869649
[No Abstract] [Full Text] [Related]
4. Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
Li J; Wang Z; Groen HJM; Zhao J; Wang P; Zhang C; Yang K; Guo Y; Ma J
Lung Cancer; 2018 Apr; 118():173-175. PubMed ID: 29502892
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Li WQ; Li LY; Chai J; Cui JW
Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
[TBL] [Abstract][Full Text] [Related]
6. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
Miyawaki T; Kenmotsu H; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
BMC Cancer; 2021 Nov; 21(1):1247. PubMed ID: 34798865
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
8. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
[TBL] [Abstract][Full Text] [Related]
10. Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
Vaid AK; Gupta A; Momi G
Int J Oncol; 2021 Feb; 58(2):171-184. PubMed ID: 33491758
[TBL] [Abstract][Full Text] [Related]
11. Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.
Chiang CL; Yeh YC; Chou TY; Chiu CH
J Formos Med Assoc; 2020 Sep; 119(9):1439-1441. PubMed ID: 32173232
[No Abstract] [Full Text] [Related]
12. Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.
Wang CC; Lai CH; Chang YP; Chang HC; Tseng CC; Huang KT; Lin MC
Thorac Cancer; 2021 Dec; 12(23):3263-3272. PubMed ID: 34704378
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.
Zhao ZM; Wang SP; Sun L; Ji YX
Chin Med J (Engl); 2020 Nov; 134(3):373-374. PubMed ID: 33186133
[No Abstract] [Full Text] [Related]
14. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
15. EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges.
Tfayli A; Mohty R
Tumori; 2021 Oct; 107(5):376-384. PubMed ID: 33153414
[TBL] [Abstract][Full Text] [Related]
16. Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Pakkala S; Ramalingam SS
Hematol Oncol Clin North Am; 2017 Feb; 31(1):83-99. PubMed ID: 27912836
[TBL] [Abstract][Full Text] [Related]
17. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
18. Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy.
Taek Kim J; Zhang W; Lopategui J; Vail E; Balmanoukian A
JCO Precis Oncol; 2021 Nov; 5():88-92. PubMed ID: 34994592
[No Abstract] [Full Text] [Related]
19. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
Lee K; Kim D; Yoon S; Lee DH; Kim SW
Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
